谈及后续有望在今年注册的产品，管理层表示，按今年已提交注册的产品时间顺序,分别为"眼科生物补 片"、"胶原纤维填充剂-I"、"复杂先心带瓣补片"、"ePTFE心包膜"、"介入肺动脉瓣及输送系统"、"消化 外科生物补片"、"卵圆孔未闭封堵器"和"胶原纤维填充剂-II",未来四个月,计划还有4款在研产品提交注 册 。 按目前注册审批进度，其中ePTFE心包膜和胶原纤维填充剂-I将在四季度有望获批，其它产品将陆续于 年底或明年第一季度和第二季度获批上市。 对于海外市场，管理层介绍，印尼海外注册已有16个产品，包括：动脉导管未闭封堵器，心血管病封堵 器输送系统，胸外科生物补片，涤纶补片，房缺封堵器，肺动脉带瓣管道，室间隔缺损封堵器，流出道 单瓣补片，心外科生物补片，三尖瓣成形环，限位可扩张人工生物心脏瓣膜，二尖瓣成形环，心脏瓣膜 生物补片，测瓣器，测环器，经导管主动脉瓣系统。市场拓展和新加坡筹备正在进行中。 还有投资者询问血管生物补片的市场前景。对此，管理层分析，公司血管生物补片主要为填补国内空 白，即因无可用产品一直未能开展的颈动脉斑块切除与血管重建术，因该手术可有效防止缺血性脑卒中 的发生。 根据王陇德院士团队有 ...

北京佰仁医疗科技股份有限公司 进展和短期快速发展战略的逐步落实，同时响应证监会、央行的政策引导，计 划自《佰仁医疗关于控股股东、实际控制人增持公司股份计划的公告》披露起 自 10 万股起，不超过 213 万股，并承诺本次增持完成后 12 个月内不减持其持 有的公司股份。截至 2025 年 3 月 27 日，公司控股股东、实际控制人以集中竞 价交易方式累计增持公司股份 124,759 股，占公司总股本的 0.0908%，增持金 额为人民币 1,377.3893 万元，该增持计划已实施完毕。 评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，落实"以投资者为本" 的发展理念，推动上市公司持续优化经营、规范治理和积极回报投资者，提高上 市公司质量，助力市场信心提振、资本市场稳定和经济高质量发展，北京佰仁医 疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日披露了《佰仁医 疗 2024 年度"提质增效重回报"专项行动方案的评估报告暨 2025 年度"提质增 效重回报"专项行动方案》。2025 年以来，公司根据行动方案内容，积极开展 和落实相关工作，现将行动方案主要工作成果报告如下： 一、聚 ...

Core Viewpoint - The article highlights the growing significance of heart valve diseases in the context of an aging population, with Beijing Bairen Medical Technology Co., Ltd. emerging as a key player in the domestic market for artificial heart valves, breaking the monopoly of foreign companies and achieving self-sufficiency in core technologies [2][3]. Company Overview - Bairen Medical is the only A-share listed company in the structural heart disease sector in China, focusing on original research and innovation for over 20 years [2]. - The company has developed a bioprosthetic valve using bovine pericardium, which surpasses imported products in anti-calcification performance and durability, addressing the long-standing reliance on imported valves for Chinese patients [2][3]. Innovation and R&D - The development of bioprosthetic valves requires advanced animal tissue engineering and chemical modification techniques, with Bairen Medical investing significantly in R&D, with a budget of 151 million yuan in 2024, a 53.26% increase year-on-year, representing 30.17% of its revenue [4]. - The company has received approval for 21 Class III medical device products, with 10 filling domestic gaps, and has launched 11 interventional products covering the entire lifecycle of heart valve treatment [4]. Market Performance - In 2024, Bairen Medical achieved a revenue of 502 million yuan, a 35.41% increase, and a net profit of 146 million yuan, a 27.02% increase, with all three business segments showing growth [5]. - The heart valve replacement and repair segment saw a revenue increase of 64.28%, with artificial biological heart valves growing by 75.06% [5]. International Expansion - Bairen Medical is entering international markets, with over ten products registered in Indonesia and plans to expand to Germany, Singapore, and Japan [6]. - The company acquired a U.S. firm, Tianqiong Innovation, to enhance its capabilities in ePTFE materials, addressing the long-standing issue of dependence on imports [6]. Regulatory and Systemic Innovations - The company aims to accelerate the market entry of high-end medical devices through regulatory innovations, advocating for transparent review standards and improved communication mechanisms in the registration process [6].